open access

Vol 65, No 5 (2014)
Original papers
Published online: 2014-10-09
Submitted: 2014-10-09
Accepted: 2014-10-09
Get Citation

Incidence and predictors of persistent growth hormone deficiency (GHD) in patients with isolated, childhood-onset GHD

Joanna Smyczyńska, Renata Stawerska, Andrzej Lewiński, Maciej Hilczer
DOI: 10.5603/EP.2014.0046
·
Endokrynologia Polska 2014;65(5):334-341.

open access

Vol 65, No 5 (2014)
Original papers
Published online: 2014-10-09
Submitted: 2014-10-09
Accepted: 2014-10-09

Abstract

Introduction: In a considerable proportion of patients with childhood-onset growth hormone (GH) deficiency (GHD), a normalisation of GH secretion at the attainment of final height (FH) is observed. The aim of the present study was to assess the incidence of, and to find out the predictors of, persistent and transient GHD, available in the pre-treatment period, in patients with childhood-onset isolated, non-acquired GHD.

Material and methods: The analysis comprised 150 short children (117 boys), with childhood-onset isolated, non-acquired GHD who completed GH therapy and attained FH. Before treatment and at FH (in retesting), auxological parameters were measured, GH peak in stimulation tests and IGF-I concentration were assessed, and pituitary height (PHt) was measured before treatment.

Results: The incidence of persistent GHD was 12.0%. The patients with persistent GHD had before treatment significantly lower GH and IGF-I secretion, as well as significantly better increase of height SDS (DHSDS) during GH therapy than those with transient GHD. A negative correlation was observed between DHSDS and IGF-I concentration, but not between DHSDS and GH peak. There was no significant difference in the incidence of pituitary hypoplasia between the patients with persistent and transient GHD.

Conclusions: The incidence of persistent GHD in patients with childhood-onset, isolated, non-acquired GHD is relatively low. Despite the fact that the predictors of persistent and transient GHD may be identified in childhood, a diagnosis of GHD should be verified in retesting after the attainment of FH in each case. (Endokrynol Pol 2014; 65 (5): 334–341)

Abstract

Introduction: In a considerable proportion of patients with childhood-onset growth hormone (GH) deficiency (GHD), a normalisation of GH secretion at the attainment of final height (FH) is observed. The aim of the present study was to assess the incidence of, and to find out the predictors of, persistent and transient GHD, available in the pre-treatment period, in patients with childhood-onset isolated, non-acquired GHD.

Material and methods: The analysis comprised 150 short children (117 boys), with childhood-onset isolated, non-acquired GHD who completed GH therapy and attained FH. Before treatment and at FH (in retesting), auxological parameters were measured, GH peak in stimulation tests and IGF-I concentration were assessed, and pituitary height (PHt) was measured before treatment.

Results: The incidence of persistent GHD was 12.0%. The patients with persistent GHD had before treatment significantly lower GH and IGF-I secretion, as well as significantly better increase of height SDS (DHSDS) during GH therapy than those with transient GHD. A negative correlation was observed between DHSDS and IGF-I concentration, but not between DHSDS and GH peak. There was no significant difference in the incidence of pituitary hypoplasia between the patients with persistent and transient GHD.

Conclusions: The incidence of persistent GHD in patients with childhood-onset, isolated, non-acquired GHD is relatively low. Despite the fact that the predictors of persistent and transient GHD may be identified in childhood, a diagnosis of GHD should be verified in retesting after the attainment of FH in each case. (Endokrynol Pol 2014; 65 (5): 334–341)

Get Citation

Keywords

short stature; growth hormone deficiency (GHD); growth hormone therapy; insulin-like growth factor-I; final height; persistent GHD; transient GHD

About this article
Title

Incidence and predictors of persistent growth hormone deficiency (GHD) in patients with isolated, childhood-onset GHD

Journal

Endokrynologia Polska

Issue

Vol 65, No 5 (2014)

Pages

334-341

Published online

2014-10-09

DOI

10.5603/EP.2014.0046

Bibliographic record

Endokrynologia Polska 2014;65(5):334-341.

Keywords

short stature
growth hormone deficiency (GHD)
growth hormone therapy
insulin-like growth factor-I
final height
persistent GHD
transient GHD

Authors

Joanna Smyczyńska
Renata Stawerska
Andrzej Lewiński
Maciej Hilczer

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl